An Open-Label Extension Study of Multiple Subcutaneous Doses of LY2127399 in Japanese Patients With Rheumatoid Arthritis Treated With Methotrexate.

Trial Profile

An Open-Label Extension Study of Multiple Subcutaneous Doses of LY2127399 in Japanese Patients With Rheumatoid Arthritis Treated With Methotrexate.

Completed
Phase of Trial: Phase I

Latest Information Update: 31 May 2016

At a glance

  • Drugs Tabalumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Sponsors Eli Lilly
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 08 Aug 2013 Planned End Date changed from 1 Oct 2013 to 1 Jun 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top